Amarin Corp Plc (AMRN)

[zumantu]

JL, re FDA
I listed to entire event, the FDA was very clear they were in possession of new science, and I believe they are not going to approve Vascepa. All studies on lipid lowering failed to produce reduction of CV events

I understand you point, but they have their backs covered on this one.

Amarin now have their backs up against the wall. I cant see anyone investors hanging 3+ years hoping for JELIS type results

major dilution coming - or a fire sale on business, hard to value now with meager sales and not enough cash . Easy pickings for BP to come along and get it cheap

Holding thru for December approval ? Sounds suicidal

FDA was clear about what to vote on- it was about guessing on reduce it, not Anchor actual data